Hollow fiber system model for tuberculosis: The European Medicines Agency experience

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S1-S4

  Cavaleri, Marco ^a   Manolis, Efthymios ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

EMA; In vitro models; PK PD; Qualification; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HOLLOW FIBER; HUMAN; IN VITRO STUDY; METHODOLOGY; MONTE CARLO METHOD; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TUBERCULOSIS; BIOLOGICAL MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PRECLINICAL STUDY; PROCEDURES;

ANTITUBERCULAR AGENTS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; IN VITRO TECHNIQUES; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84942121678     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ484     Document Type: Article

References (12)

1. Pasipanodya J, Nuermberger E, Romer K, Hanna D, Gumbo T. Systematic analysis of hollow fiber model of tuberculosis experiments. Clin Infect Dis 2015; 61(suppl 1):S10-7.
2. Drusano GL, Neely M, Van Guilder M, et al. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One 2014; 9:e101311.
3. Romero K, Clay R, Hanna D. Strategic regulatory evaluation and endorsement of the hollow fiber tuberculosis system as a novel drug development tool. Clin Infect Dis 2015; 61(suppl 1):S5-9.
4. European Medicines Agency. Road map to 2015. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Report/2011/01/WC500101373.pdf. Accessed 30 June 2015.
5. European Medicines Agency. Novel methodologies webpage. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document-listing/document-listing-000319.jsp&mid=WC0b01ac0580022bb0. Accessed 30 June 2015.
6. Manolis E, Koch A, Deforce D, Vamvakas S. The European Medicines Agency experience with biomarker qualification clinical proteomics. Methods Mol Biol 2015; 1243:255-72.
7. Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother 1985; 15(suppl A):131-7.
8. Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D. Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin Infect Dis 2015; 61(suppl 1):S18-24.
9. Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D. Forecasting accuracy of the hollow fiber system model of tuberculosis for clinical therapeutic outcomes. Clin Infect Dis 2015; 61(suppl 1):S25-31.
10. European Medicines Agency. Draft concept paper on revision of the points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products (CHMP/EWP/2655/99) and conversion to a CHMP guideline. Available at: http://www.ema.europa.eu/ema/doc-index.jsp?curl=pages/includes/document/document-detail.jsp?webContentId=WC500162135&murl=menus/document-library/document-library.jsp&mid=0b01ac058009a3dc. Accessed 30 June 2015.
11. European Medicines Agency. Final qualification opinion. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2015/02/WC500181899.pdf. Accessed 30 June 2015.
12. European Medicines Agency. Concept paper on revision of the addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections to specifically address the clinical development of new agents to treat disease due to Mycobacterium tuberculosis. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/11/WC500177902.pdf. Accessed 30 June 2015.